2. Disease Areas
  3. Neurological, Eye or Ear Disease
  4. Neurodegenerative Disease
  5. Alzheimer's Disease

Alzheimer's Disease

Alzheimer's disease is a progressive neurodegenerative disorder characterized by cognitive decline, particularly in memory and learning, due to synaptic loss and the accumulation of amyloid-beta plaques and neurofibrillary tangles in the brain, leading to clinical dementia.

Alzheimer's Disease (2194):

Cat. No. 상품명 CAS No. Purity 화학구조
  • HY-10182
    Laduviglusib 252917-06-9 99.76%
    Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy.
    Laduviglusib
  • HY-12318
    IBMX 28822-58-4 99.99%
    IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor, with IC50s of 6.5, 26.3 and 31.7 μM for PDE3, PDE4 and PDE5, respectively.
    IBMX
  • HY-13027
    DAPT 208255-80-5 99.97%
    DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment.
    DAPT
  • HY-10181
    Dasatinib 302962-49-8 99.85%
    Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy, and can cross the blood-brain barrier.
    Dasatinib
  • HY-100545
    BAPTA-AM 126150-97-8 99.68%
    BAPTA-AM is a well-known membrane permeable Ca2+ chelator. BAPTA-AM inhibits hERG channels, hKv1.3 and hKv1.5 channels in HEK 293 cells with IC50s of 1.3 μM, 1.45 μM and 1.23 μM, respectively.
    BAPTA-AM
  • HY-D0005
    Bathocuproine 4733-39-5
    Bathocuproine is a phenanthroline chelator that binds specifically to Cu+. Bathocuproine preferentially binds Cu+ over Cu2+ to form a chromogenic complex, which is used to detect the oxidation state of copper in biomolecules. Bathocuproine undergoes concentration-dependent self-association to form dimers, and it can engage in aromatic stacking interactions with aromatic residues of Aβ (Kd ≈ 1 mM). Bathocuproine is applicable to research related to Alzheimer's disease.
    Bathocuproine
  • HY-137570
    Ethyl homovanillate 60563-13-5 98.41%
    Ethyl homovanillate (Compound 24) is an structural analog of Eugenol. Ethyl homovanillate is an inhibitor of monoamine oxidase A (MAOA) with an IC50 of 8.1 μM. Ethyl homovanillate significantly increases the forced swim test score in ICR mice. Ethyl homovanillate can be studied in research on neurological diseases such as Alzheimer’s disease.
    Ethyl homovanillate
  • HY-W841438
    Lithium orotate 5266-20-6
    Lithium orotate is an orally active lithium supplement with reduced binding that can bypass amyloid sequestration in AD mice models. Lithium orotate can prevent Aβ plaque deposition and phospho-tau accumulation and reverse AD pathology, neuroinflammatory changes and memory loss in AD mice models and ageing wild-type mice. Lithium orotate can be used for the research of alcoholism and Alzheimer’s disease.
    Lithium orotate
  • HY-13520
    Nocodazole 31430-18-9 99.59%
    Nocodazole (Oncodazole) is a rapidly-reversible inhibitor of microtubule. Nocodazole binds to β-tubulin and disrupts microtubule assembly/disassembly dynamics, which prevents mitosis and induces apoptosis in tumor cells. Nocodazole inhibits Bcr-Abl.
    Nocodazole
  • HY-B0764
    Bucladesine sodium 16980-89-5 99.36%
    Bucladesine (Dibutyryl cAMP; DBcAMP) sodium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation.
    Bucladesine sodium
  • HY-12305
    Q-VD-OPh 1135695-98-5 99.92%
    Q-VD-OPh is an irreversible pan-caspase inhibitor with potent antiapoptotic properties; inhibits caspase 7 with an IC50 of 48 nM and 25-400 nM for other caspases including caspase 1, 3, 8, 9, 10, and 12. Q-VD-OPh can inhibits HIV infection. Q-VD-OPh is able to cross the blood-brain barrier.
    Q-VD-OPh
  • HY-P0175
    740 Y-P 1236188-16-1 99.67%
    740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone.
    740 Y-P
  • HY-F0004
    Fosribnicotinamide 1094-61-7 99.94%
    Fosribnicotinamide (β-nicotinamide mononucleotide) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity.
    Fosribnicotinamide
  • HY-16569
    Colchicine 64-86-8 99.86%
    Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research.
    Colchicine
  • HY-15463
    Imatinib 152459-95-5 99.95%
    Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.
    Imatinib
  • HY-123033A
    Nicotinamide riboside chloride 23111-00-4 99.90%
    Nicotinamide riboside Chloride, an orally active NAD+ precursor, increases NAD+ levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities. Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease.
    Nicotinamide riboside chloride
  • HY-B0282
    Acetylcholine chloride 60-31-1 99.91%
    Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent and BBB-permeable cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs). Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro.
    Acetylcholine chloride
  • HY-44134
    Dimethyl 2-oxoglutarate 13192-04-6
    Dimethyl 2-oxoglutarate (Dimethyl α-ketoglutarate) is a cell-permeable derivative of 2-oxoglutarate and tricarboxylic acid cycle metabolite with antioxidant properties. Dimethyl 2-oxoglutarate inhibits Autophagy. Dimethyl 2-oxoglutarate prevents mitochondrial damage and reduces ROS production. Dimethyl 2-oxoglutarate alleviates Carbon tetrachloride (HY-Y0298)-induced liver fibrosis. Dimethyl-2-oxoglutaric acid can be used in the research of diseases such as Alzheimer's disease, diabetes, and cardiomyopathy.
    Dimethyl 2-oxoglutarate
  • HY-100714A
    D-AP5 79055-68-8 99.94%
    D-AP5 (D-APV) is a selective and competitive NMDA receptor antagonist with a Kd of 1.4 μM. D-AP5 (D-APV) inhibits the glutamate binding site of NMDA receptors.
    D-AP5
  • HY-B0573
    Propranolol hydrochloride 318-98-9 99.95%
    Propranolol hydrochloride is a nonselective and BBB-permeableβ-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively. Propranolol hydrochloride inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM. Propranolol hydrochloride is used for study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.
    Propranolol hydrochloride